However, for RCC, these second-line treatment options remain limited to drugs with similar mechanisms of action, primarily tyrosine kinase inhibitors (TKIs) targeting vascular endothelial growth factor receptors (VEGFR) and immune checkpoint inhibitors [5]. This evidence concerns the gene KDR and renal cell carcinoma.